CN109432103A - 齐墩果酸在制备β内酰胺酶抑制剂中的医用用途 - Google Patents

齐墩果酸在制备β内酰胺酶抑制剂中的医用用途 Download PDF

Info

Publication number
CN109432103A
CN109432103A CN201811365552.7A CN201811365552A CN109432103A CN 109432103 A CN109432103 A CN 109432103A CN 201811365552 A CN201811365552 A CN 201811365552A CN 109432103 A CN109432103 A CN 109432103A
Authority
CN
China
Prior art keywords
beta
oleanolic acid
lactamase
drug
activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201811365552.7A
Other languages
English (en)
Other versions
CN109432103B (zh
Inventor
邓旭明
周永林
王建锋
郭岩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jilin University
Original Assignee
Jilin University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jilin University filed Critical Jilin University
Priority to CN201811365552.7A priority Critical patent/CN109432103B/zh
Publication of CN109432103A publication Critical patent/CN109432103A/zh
Application granted granted Critical
Publication of CN109432103B publication Critical patent/CN109432103B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

本发明提供一种齐墩果酸在制备β内酰胺酶抑制剂中的医用用途，通过β‑内酰胺酶活性检测试验、微量肉汤稀释棋盘法、时间‑杀菌曲线试验验证了齐墩果酸能够抑制β‑内酰胺酶的活性并恢复青霉素等β‑内酰胺类抗生素对β‑内酰胺酶阳性菌（包括金黄色葡萄球菌、大肠杆菌和肺炎克雷伯氏菌）的抗菌活性。因此齐墩果酸作为β‑内酰胺酶抑制剂可以与抗生素联用，增加对耐药菌使用药物的选择性，对开发抗β‑内酰胺酶菌感染新药有着重要意义。

Description

齐墩果酸在制备β内酰胺酶抑制剂中的医用用途
技术领域
本发明公开了齐墩果酸的一种新的用途，进一步讲涉及齐墩果酸在制备β-内酰胺酶抑制剂中的医用用途，属于医学制药技术领域。
背景技术
细菌耐药性的问题已经成为全球的一个关注热点，其中以耐β-内酰胺类抗生素的金黄色葡萄球菌、大肠杆菌和肺炎克雷伯氏菌较为严重。耐药菌感染导致β-内酰胺类抗生素的治疗失败和较高的死亡率，给治疗院内感染、特别是治疗ICU感染带来了更大的压力。
β-内酰胺酶抑制剂在市场上已流通，但是该类抑制剂亦属于抗生素衍生物，本身具有一定的抗菌活性，通过使用时极易产生耐药性。齐墩果酸属于中药活性成分，对所检测的几种致病菌无抗菌活性。因此，开发齐墩果酸作为新型β-内酰胺酶抑制剂具有十分重要的意义。齐墩果酸为存在于女贞子、齐墩果和罗锅地等多种植物中。齐墩果酸有抗炎、抗肿瘤和增强免疫力的作用。目前大量研究表明齐墩果酸在抗病毒感染的治疗和防护中有较好的作用。
发明内容
本发明提供了一种齐墩果酸在制备β-内酰胺酶抑制剂中的医用用途，公开了齐墩果酸能够抑制β-内酰胺酶的活性，恢复β-内酰胺类抗生素对携带β-内酰胺酶金黄色葡萄球菌、大肠杆菌和肺炎克雷伯氏菌的杀菌活性。
本发明所述的齐墩果酸，其分子式：C30H48O3，分子量：456.70；
本发明通过β-内酰胺酶活性检测、棋盘法最小抑菌浓度和时间-杀菌曲线法验证齐墩果酸能够抑制β内酰胺酶的活性并恢复β-内酰胺类抗生素对β内酰胺类抗生素耐药的金黄色葡萄球菌、大肠杆菌和肺炎克雷伯氏菌抗菌活性。
本发明的积极效果在于：
提供了齐墩果酸在制备β-内酰胺酶抑制剂中的新医用用途，公开了齐墩果酸能够抑制β内酰胺酶的活性，恢复青霉素对携带β-内酰胺酶金黄色葡萄球菌、大肠杆菌和肺炎克雷伯氏菌的杀菌活性。
附图说明
图1为本发明检测不同浓度齐墩果酸对主要β-内酰胺酶的活性影响结果；
图2为本发明齐墩果酸联合β-内酰胺类抗生素对携带β-内酰胺酶金黄色葡萄球菌、大肠杆菌的时间-杀菌曲线。
具体实施方式
通过以下实施例进一步举例描述本发明，并不以任何方式限制本发明，在不背离本发明的技术解决方案的前提下，对本发明所作的本领域普通技术人员容易实现的任何改动或改变都将落入本发明的权利要求范围之内。
实施例1
齐墩果酸作为β内酰胺酶抑制剂用于药学上可接受的任何载体。
实施例2
齐墩果酸作为β内酰胺酶抑制剂用于制备治疗感染性疾病的药物。
实施例3
齐墩果酸作为β内酰胺酶抑制剂用于治疗细菌引起的感染性疾病。
试验例1
β-内酰胺酶活性鉴定
过夜培养表达β-内酰胺酶的金葡菌和携带NDM-1的大肠杆菌，备用。取无菌试管3只分别加入0 μg/mL、8 μg/mL和32μg/mL齐墩果酸，之后每管内均加入10 μL过夜培养的金葡菌和携带NDM-1的大肠杆菌菌液，于37 ℃恒温摇床中，200rpm培养3 h，12000g，4 ℃离心5min后分别取上清50μL与无菌96孔板中，加入25 μL头孢硝噻吩作为底物，加入PBS(磷酸盐缓冲液)125 μL，于37 ℃恒温培养箱中静止孵育1 h左右，通过观察颜色变化和492 nm出吸光值来判定β-内酰胺酶活性。结果见表1和附图1。
表 1 共培养后齐墩果酸对β-内酰胺酶活性抑制效果
同时，构建携带不同耐药酶的工程菌，表达活性耐药酶。检测耐药酶活性并确定一个最佳的耐药酶浓度，加入PBS(磷酸盐缓冲液)174 μL与无菌96孔板中，并加入活性耐药酶1 ul震荡孵育30 min，然后加入25 μL头孢硝噻吩作为底物，于37 ℃恒温培养箱中静止孵育1 h左右，通过观察颜色变化和492 nm出吸光值来判定β-内酰胺酶活性。结果见表2。
表2 共孵育后齐墩果酸对β-内酰胺酶活性抑制效果
结论：齐墩果酸与金黄色葡萄球菌USA300共培养后可降低分泌到上清中的β-内酰胺酶的活性。同时，纯化的β-内酰胺酶与齐墩果酸共同孵育，可降低β-内酰胺酶的活性。
试验例2 最小抑菌浓度试验
于96孔无菌微孔板内按棋盘法进行齐墩果酸、青霉素单用及二者联用抗产β内酰胺酶金葡菌的抑菌活性实验，确定二者单独应用及联合应用MIC值，计算部分抑菌浓度指数(FIC)。 FIC=MIC(青霉素联合)/MIC(青霉素单用)+MIC(齐墩果酸联合)/MIC(齐墩果酸单用)，结果见表3：
表 3 齐墩果酸联用青霉素对表达β内酰胺酶金黄色葡萄球菌的MIC及FIC值
结论：齐墩果酸单独应用不具备抑菌效果，与青霉素联用能够降低青霉素对β-内酰胺酶阳性金葡菌MIC值8倍，FIC数值表明二者具有协同作用。
试验例3 时间-杀菌曲线试验
取表达β内酰胺酶的金葡菌过夜培养物，调整至5×107 CFUs/mL，备用。取无菌试管3组（无抗生素对照组、4 μg/mL青霉素组及32 μg/mL齐墩果酸联用4 μg/mL青霉素组），每组标记为1、3、5、7 和9h，所有试管内均加入1 mL高压灭菌的LB培养基，之后，每管内均加入10 μL调整后的菌液，使每个试管内的菌液浓度为5×105 CFUs/mL。其中4 μg/mL青霉素组及32μg/mL齐墩果酸联用4 μg/mL青霉素组分别加入对应用量的抗生素及抑制剂，混匀之后立即将无抗生素对照组的菌液进行涂板计数，作为0 h的菌落数。之后，每1、3、5、7及9 h分别取对应试管内的菌液，涂板计数，绘制时间-杀菌曲线（图2）。
结论：齐墩果酸联用青霉素能够在7h后杀死表达β内酰胺酶金葡菌USA300。

Claims (5)

1.齐墩果酸在制备β-内酰胺酶抑制剂中的用途。
2.齐墩果酸在制备治疗感染性疾病的药物中的用途。
3.如权利要求2所述的齐墩果酸在制备治疗感染性疾病的药物中的用途，其特征在于所述的感染性疾病指由细菌引起的感染。
4.如权利要求2所述的齐墩果酸在制备治疗感染性疾病的药物中的用途，其特征在于所述的细菌感染是指由携带β-内酰胺酶的金黄色葡萄球菌、大肠杆菌和肺炎克雷伯氏菌引起的感染。
5.以齐墩果酸为活性成分制备的β-内酰胺酶抑制剂，其特征在于所述的齐墩果酸为药学上可接受的载体。
CN201811365552.7A 2018-11-16 2018-11-16 齐墩果酸在制备β内酰胺酶抑制剂中的医用用途 Active CN109432103B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201811365552.7A CN109432103B (zh) 2018-11-16 2018-11-16 齐墩果酸在制备β内酰胺酶抑制剂中的医用用途

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201811365552.7A CN109432103B (zh) 2018-11-16 2018-11-16 齐墩果酸在制备β内酰胺酶抑制剂中的医用用途

Publications (2)

Publication Number Publication Date
CN109432103A true CN109432103A (zh) 2019-03-08
CN109432103B CN109432103B (zh) 2021-03-23

Family

ID=65554460

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201811365552.7A Active CN109432103B (zh) 2018-11-16 2018-11-16 齐墩果酸在制备β内酰胺酶抑制剂中的医用用途

Country Status (1)

Country Link
CN (1) CN109432103B (zh)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112755024A (zh) * 2020-12-31 2021-05-07 青海师范大学 一种青霉素增效减量联合抑菌剂及其制备方法
CN113384587A (zh) * 2021-08-06 2021-09-14 吉林大学 委陵菜酸在制备碳青霉烯酶抑制剂中的应用
CN113712975A (zh) * 2021-09-12 2021-11-30 东北农业大学 氨磷汀作为ndm-1抑制剂或抗生素保护剂的新用途
CN113750084A (zh) * 2021-09-12 2021-12-07 东北农业大学 酞磺醋胺作为ndm-1抑制剂或抗生素保护剂的新用途
CN115501237A (zh) * 2022-10-27 2022-12-23 五邑大学 齐墩果酸衍生物在制备抑菌药物中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1739526A (zh) * 2005-09-08 2006-03-01 易以木 齐墩果酸口服缓释片剂的制备方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1739526A (zh) * 2005-09-08 2006-03-01 易以木 齐墩果酸口服缓释片剂的制备方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
胡焱等: "齐墩果酸的抗菌作用研究进展", 《中国新药杂志》 *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112755024A (zh) * 2020-12-31 2021-05-07 青海师范大学 一种青霉素增效减量联合抑菌剂及其制备方法
CN113384587A (zh) * 2021-08-06 2021-09-14 吉林大学 委陵菜酸在制备碳青霉烯酶抑制剂中的应用
CN113712975A (zh) * 2021-09-12 2021-11-30 东北农业大学 氨磷汀作为ndm-1抑制剂或抗生素保护剂的新用途
CN113750084A (zh) * 2021-09-12 2021-12-07 东北农业大学 酞磺醋胺作为ndm-1抑制剂或抗生素保护剂的新用途
CN113712975B (zh) * 2021-09-12 2023-08-29 东北农业大学 氨磷汀作为ndm-1抑制剂或抗生素保护剂的新用途
CN115501237A (zh) * 2022-10-27 2022-12-23 五邑大学 齐墩果酸衍生物在制备抑菌药物中的应用
CN115501237B (zh) * 2022-10-27 2023-09-05 五邑大学 齐墩果酸衍生物在制备抑菌药物中的应用

Also Published As

Publication number Publication date
CN109432103B (zh) 2021-03-23

Similar Documents

Publication Publication Date Title
CN109432103A (zh) 齐墩果酸在制备β内酰胺酶抑制剂中的医用用途
KR101908411B1 (ko) 신규한 국내형 메티실린-내성 황색포도상구균 균주 및 이를 이용한 바이오필름 억제제 스크리닝 방법
US11654166B2 (en) Therapeutic bacteriophage compositions for treating Staphylococcus infection
Adu et al. The effects of Acanthospermum hispidum extract on the antibacterial activity of amoxicillin and ciprofloxacin
Gottaslo et al. Effects of oxygen on in-vitro biofilm formation and antimicrobial resistance of Pseudomonas aeruginosae
Goli et al. Prevalence and molecular characterization of Class 1 integrons among clinical isolates of Pseudomonas aeruginosa in Northwest of Iran
Prasanna et al. A profile of methicillin resistant Staphylococcus aureus infection in the burn center of the Sultanate of Oman
Ozkan et al. Lytic activity of various phage cocktails on multidrug-resistant bacteria
CN101543499A (zh) 一种天然化合物熊果酸在抗菌方面的应用
CN108420814A (zh) 一种nps-2143用于抗菌的新用途
Kariuki et al. Antimicrobial susceptibility in community-acquired bacterial pneumonia in adults
CN108938623A (zh) 异土木香内酯在制备β内酰胺酶抑制剂中的医用用途
Adeshina et al. Antibacterial susceptibility of Klebsiella pneumoniae isolates from respiratory tract infections to honey and lemon
Michel et al. Bactericidal synergistic effect due to chloramphenicol-induced inhibition of staphyloccal penicillinase
Jahan et al. In vitro evaluation of antibacterial potential of Stevia rebaudiana Bertoni against various bacterial pathogens including resistant isolates with bla genes
Babushkina et al. Resistance to Antibiotics in Plankton and Biofilm Cultures of Pseudomonas aeruginosa Clinical Strains
Ghosh Does bitter melon (Momordica charantia) have antibacterial property?
Yourassowsky et al. Rate of bactericidal activity for Branhamella catarrhalis of a new macrolide, CP-62,993, compared with that of amoxicillin-clavulanic acid
Hussein Antibacterial Activity of Lantana camara Flower Extracts Against Growth of Pathogenic Bacteria Isolated from Wounds and Burns Infections
Sarkar et al. Anti-bacterial activity of homoeopathic medicine Sulphanilamide against Staphylococcus epidermidis in-vitro
CN112076184B (zh) 苄丝肼作为抗细菌剂的应用
CN115154468B (zh) 地氯雷他定在制备抗菌药物中的应用
Kaur et al. Antibiotic Resistance and Biofilm Formation Among Nosocomial Pathogens in a Tertiary Care Hospital
Kwitko et al. Serratia: opportunistic pathogen of increasing clinical importance
Hossain et al. Antibiotic susceptibility pattern of clinical isolates of Escherichia coli at a tertiary care hospital

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant